Vishwanath
Lingappa

The man who walked away from tenure

In 2004, Vishwanath Lingappa had a job most scientists would do anything to keep: tenured faculty at UCSF, research funding from the NIH, and 22 years of academic infrastructure behind him. He left anyway.

He had a platform - a Cell-Free Protein Synthesis System he'd spent years developing - and a theory that it could find drugs at a class of targets the entire pharmaceutical industry had been ignoring. Multi-protein complexes: transient, energy-dependent assemblies that form briefly inside cells, do critical work, and then dissolve. Traditional high-throughput screening can't touch them. Lingappa's system can.

So he founded Prosetta Biosciences in San Francisco's SoMa neighborhood and started building. Twenty-five people. Partnerships with Takeda, Bristol-Myers Squibb, AstraZeneca. Over $35 million in non-dilutive government contracts. A presence in the Scripps Research Institute's NIH-funded Center for Pandemic Preparedness - where Prosetta is the only biotech company.

The logic is disarmingly simple once you hear it: if every major pharma company is screening the same types of targets with the same types of assays, they'll find the same types of drugs. What nobody screens for, nobody finds. Lingappa built a machine to find what nobody else is looking for.

Lafayette, Indiana. Worcester, Massachusetts. Rockefeller University.

He was born in 1954 in Lafayette, Indiana, where his father B.T. Lingappa was finishing his doctorate at Purdue. His parents were Indian immigrants who had done something considered almost scandalous in 1940s India: a love marriage across Brahmin subcastes. His mother Yamuna wrote a story about two star-crossed lovers searching for knowledge before they married his father. Both parents would go on to become academics, eventually settling in Worcester, Massachusetts to teach and research at Holy Cross College.

Academic ambition was ambient in the Lingappa household. All three children - Vishwanath, his brother Jairam, and his sister Jaisri - would earn doctoral degrees. All three would eventually become involved with Prosetta Biosciences.

Lingappa graduated from Swarthmore College in 1975 with a B.A. with High Honors, then enrolled at The Rockefeller University. He became the first graduate student of Gunter Blobel, a German cell biologist who had proposed the signal hypothesis for how proteins get targeted to the endoplasmic reticulum. Lingappa's doctoral work in 1979 focused on exactly that: the mechanism by which nascent proteins are directed across cell membranes.

Twenty years later, in 1999, Blobel won the Nobel Prize in Physiology or Medicine for that work. By then, Vishwanath Lingappa was three time zones away, building something of his own.

22 years, 157 papers, one Kaiser Award

After completing both his PhD and MD - the latter from Cornell University Medical College in 1980 - Lingappa joined UCSF's faculty in 1982, splitting his time across the Departments of Physiology and Medicine. He maintained an NIH-funded research laboratory, taught medical students and residents, and practiced general internal medicine. The range was unusual: most researchers at that level pick one lane. He kept all three open.

In 1990 he received the Kaiser Award for Teaching Excellence - a recognition of his classroom presence, which colleagues and students have described as something between a radio host and a conductor. One account captures it: a voice of "dramatic pianissimos and booming crescendos like a Beethoven symphony." His brother Jairam describes a childhood scene that illuminates the same quality: during TV commercial breaks, Vishwanath would challenge him to run downstairs, make a peanut-butter-and-jelly sandwich with a glass of milk, and return upstairs - in under one minute. The demand was playful. The expectation was non-negotiable.

By 2004, he had accumulated 22 years of UCSF faculty life, a substantial publication record, and a platform technology he believed could change the economics of drug discovery. The institution offered stability. The idea required risk. He chose the idea.

He is now Professor Emeritus of Physiology and Medicine at UCSF - keeping the title, surrendering the office, taking the bet.

25 people. Four disease categories. One radical premise.

Prosetta currently runs programs across four major disease areas simultaneously - which for a 25-person company sounds either visionary or reckless, depending on how you feel about platforms versus focus. Lingappa's argument is that the platform is the focus: if your discovery engine is genuinely disease-agnostic, restricting it to one indication is just leaving money and medicine on the table.

Neurodegeneration: The company is advancing PAV-615, an assembly modulator being tested in preclinical models of ALS and FTD. Separately, oxidized MIF is under investigation as a therapeutic target in Alzheimer's disease. Both programs build on Lingappa's decades of research into how protein misassembly drives neuronal death - work that includes a landmark 1998 paper on transmembrane prion proteins in neurodegeneration that has been cited nearly 1,000 times.

Oncology: Two chemotypes - PAV-617 and PAV-951 - are showing pan-cancer cytotoxicity in testing. A third compound, PAV-541, is also in development. The oncology program drew enough attention to win an ARPA-H Dash to Accelerate Health Outcomes competition, with a submission titled "One Drug For All Cancers." Prosetta is now working with the National Cancer Institute to advance candidates toward FDA Phase I clinical trials.

Infectious Diseases: Before COVID vaccines existed, Prosetta was developing broad-spectrum antivirals - small molecules effective against influenza, HIV, hepatitis C, rabies, dengue, chikungunya, and mpox. In January 2021, the company announced novel drug candidates effective against COVID-19, influenza, and the common cold, with the explicit claim of no drug resistance liability. The mechanism: rather than targeting the virus directly, the drugs modulate host cell assembly machinery the virus needs to replicate.

The Scripps Research partnership is the institutional confirmation of the approach's credibility. Prosetta is the sole biotech inside a center otherwise populated by academic labs - a structure that gives the company early access to emerging pathogen intelligence and collaborative validation that money alone can't buy.

The record

The citation record

Lingappa's most-cited work spans membrane biology, prion diseases, steroidogenesis, and virology - reflecting a researcher who followed mechanisms across disease categories rather than committing to any single one.

The arc

Find Vishwanath Lingappa